Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 9, Number 10—October 2003

Research

Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada

Brian Clarke*, Margot Hiltz*, Heather Musgrave*, and Kevin R. Forward*Comments to Author 
Author affiliations: *Dalhousie University and the Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

Main Article

Table 2

Effect of serial passage on cefoxitin gradient on promoter and attenuator regions and outer membrane protein profiles of laboratory wild type Escherichia colia,b

Strain MIC before serial passage (μg/mL) MIC after serial passage (μg/mL) Outer membrane protein profile
LD1
<2
>32
None
LD2
<2
>32
Omp C-, Omp F-
LD3
<2
16
Omp C-, Omp F-
LD4
<2
>32
Omp C-, Omp F-
LD5
<2
>32
Omp C-, Omp F-
LD6
<2
8
Not done
LD7
<2
4
Not done
LD8
<2
16
Omp C-, Omp F-
LD9
<2
>32
Omp C- , Omp F-
LD10 <2 >32 Decreased production of OmpC/F

aOnly those mutations that arose following serial passage are shown. Some parental strains had mutations initially, which were retained in the mutants.
bNo promoter/attenuator mutations affected β-lactamase production.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO